The management of pregnancy in Gaucher disease

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 156, Issue 1, 2011, Pages 3-8

  Granovsky Grisaru, Sorina ^a   Belmatoug, Nadia ^b   Vom Dahl, Stephan ^c   Mengel, Eugen ^d   Morris, Elizabeth ^e   Zimran, Ari ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITY OF COLOGNE   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Delivery; Enzyme replacement therapy; Gaucher disease; Imiglucerase; Pregnancy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMIGLUCERASE;

BREAST FEEDING; CALCIUM INTAKE; CLINICAL ASSESSMENT; CYANOCOBALAMIN DEFICIENCY; DELIVERY; DIAGNOSTIC IMAGING; ECHOGRAPHY; GAUCHER DISEASE; GENETIC COUNSELING; HUMAN; LABOR MANAGEMENT; MATERNAL CARE; NUTRITIONAL STATUS; ORAL CONTRACEPTION; PHYSICIAN; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 79955593513     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2010.12.024     Document Type: Review

References (24)

1. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Sly WS, Barton C, Beaudet AL, Valle D, Kinzler K, Vogelstein B, editors. The metabolic and molecular basis of inherited disease. New York, NY: McGraw-Hill; 2001. p. 3635-68.
2. Granovsky-Grisaru S, Aboulafia Y, Diamant YZ, Horowitz M, Abrahamov A, Zimran A. Gynecologic obstetric aspects of Gaucher's disease: a survey of 53 patients. Am J Obstet Gynecol 1995;172(4 Pt 1):1284-90.
3. Zimran A, Morris E, Mengel E, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 2009;43(3):264-88.
4. Elstein Y, Eisenberg V, Granovsky-Grisaru S, et al. Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol 2004;190(2):435-41. (Pubitemid 38249241)
5. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113(2):112-9. (Pubitemid 34804747)
6. Zimran A, Altarescu G, Elstein D. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol Dis 2010 [Epub ahead of print].
7. FDA (Food and Drug Administration), 2005 Cerezyme label information: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/20367s066lbl.pdf.
8. EMA (European Medicines Agency), 2008 Cerezyme SmPC: http://www.emea. europa.eu/humandocs/PDFs/EPAR/Cerezyme/H-157-en8b.pdf.
9. Royal College of Obstetricians and Gynaecologists. Management of monochorionic twin pregnancy. Gree-top guideline No. 51. http://www.rcog.org.uk/ womens-health/clinical-guidance/management-monochorionic-twin-pregnancy.
10. Sherer Y, Dulitzki M, Levy Y, Livneh A, Shoenfeld Y, Langevitz P. Successful pregnancy outcome in a patient with Gaucher's disease and antiphospholipid syndrome. Ann Hematol 2002;81(3):161-3. (Pubitemid 36067597)
11. Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis 2008;40(3):428-32. (Pubitemid 351512343)
12. Hughes D, Cappellini MD, Berger M, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 2007;138(6):676-86. (Pubitemid 47313204)
13. Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008;31(3):319-36.
14. Grabowski GA. Gaucher disease: considerations in prenatal diagnosis. Prenat Diagn 2000;20(1):60-2. (Pubitemid 30071794)
15. FDA (Food and Drug Administration), 2008 Zavesca label information: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/021348s005lbl.pdf.
16. Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004;104(5):1253-7. (Pubitemid 39166496)
17. Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009;44(3):428-30.
18. Rutgers-Verhage AR, deVries TW, Torringa MJ. No effects of bisphosphonates on the human fetus. Birth Defects Res A Clin Mol Teratol 2003;67(3):203-4.
19. Gielchinsky Y, Elstein D, Green R, et al. High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population. Br J Haematol 2001;115(3):707-9. (Pubitemid 34015666)
20. Dickinson CJ. Does folic acid harm people with vitamin B12 deficiency? QJM 1995;88(5):357-64.
21. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB, Advisory Committee on Immunization Practices (ACIP); Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-8):1-40.
22. Food and Nutrition Board of the Institute of Medicine: dietary reference intakes for calcium and vitamin D. National Academy of Sciences; 2010 , Available at: http://www.iom.edu.
23. Mikosch P, Reed M, Stettner H, Baker R, Mehta AB, Hughes DA. Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry. Mol Genet Metab 2009;96(3):113-20.
24. Gillis S, Hyam E, Abrahamov A, Elstein D, Zimran A. Platelet function abnormalities in Gaucher disease patients. Am J Hematol 1999;61(2):103-6. (Pubitemid 29252386)